Back

VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils

Ma, Y.-H. V.; Sparkes, A.; Gariepy, J.

2021-10-18 immunology
10.1101/2021.10.17.464340 bioRxiv
Show abstract

V-domain immunoglobulin suppressor of T-cell activation (VISTA) has emerged as a unique immunoregulatory receptor on cells of the myeloid lineage. Agonizing VISTA on myeloid cells has recently been demonstrated to have a profound effect on dampening inflammatory responses. VISTA has been proposed to function both as a ligand and as a receptor. In this context, the role of VISTA as a ligand has been largely ignored. Using a high-avidity agonist of the VISTA receptor (VISTA-COMP), we investigated the effect of exogenous VISTA, as a ligand, on macrophages and neutrophil cellular pathways in an acute inflammatory setting. RNA sequencing analysis demonstrated that VISTA-COMP downregulates pro-inflammatory cytokines and chemokines and upregulates immunoregulatory genes in both LPS-stimulated macrophages and neutrophils ex vivo. Interestingly, unlike VISTA itself, the receptor is only expressed following LPS stimulation of these cell populations. Furthermore, the administration of VISTA-COMP attenuated the rise in circulating TNF levels in LPS-treated mice in vivo. These results suggest that VISTA serves a redundant role on macrophages and neutrophils acting as both a ligand and a receptor in the context of an acute inflammatory event.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Journal of Leukocyte Biology
40 papers in training set
Top 0.1%
10.1%
2
eLife
5422 papers in training set
Top 7%
9.1%
3
The Journal of Immunology
146 papers in training set
Top 0.1%
8.4%
4
Science Signaling
55 papers in training set
Top 0.1%
6.8%
5
Frontiers in Immunology
586 papers in training set
Top 2%
4.9%
6
Scientific Reports
3102 papers in training set
Top 24%
4.9%
7
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 20%
3.6%
8
Cell Reports
1338 papers in training set
Top 17%
3.1%
50% of probability mass above
9
Nature Communications
4913 papers in training set
Top 43%
2.7%
10
iScience
1063 papers in training set
Top 10%
2.1%
11
Journal of Clinical Investigation
164 papers in training set
Top 2%
1.9%
12
International Journal of Molecular Sciences
453 papers in training set
Top 6%
1.9%
13
Cell Communication and Signaling
35 papers in training set
Top 0.3%
1.9%
14
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.8%
15
PLOS ONE
4510 papers in training set
Top 54%
1.7%
16
Cell Chemical Biology
81 papers in training set
Top 2%
1.7%
17
PLOS Biology
408 papers in training set
Top 10%
1.7%
18
JCI Insight
241 papers in training set
Top 4%
1.3%
19
ImmunoHorizons
21 papers in training set
Top 0.1%
1.3%
20
Science Advances
1098 papers in training set
Top 23%
1.2%
21
Journal of Biological Chemistry
641 papers in training set
Top 3%
1.1%
22
Cellular & Molecular Immunology
14 papers in training set
Top 1%
1.1%
23
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 7%
0.9%
24
Molecular Immunology
14 papers in training set
Top 0.3%
0.9%
25
mBio
750 papers in training set
Top 10%
0.9%
26
Immunology
29 papers in training set
Top 0.9%
0.8%
27
Science Translational Medicine
111 papers in training set
Top 6%
0.7%
28
European Journal of Immunology
57 papers in training set
Top 0.6%
0.7%
29
Cells
232 papers in training set
Top 7%
0.7%
30
Life Science Alliance
263 papers in training set
Top 2%
0.6%